Description
Description
What is this medicine for?
This combination helps to control high blood pressure when one or two medicines alone are not enough.
Pharmacological Classification
- Telmisartan: Angiotensin II Receptor Blocker (ARB)
- Amlodipine: Dihydropyridine Calcium Channel Blocker (CCB)
- Chlorthalidone: Thiazide-like Diuretic
Mechanism of Action
- Telmisartan: Selectively antagonizes angiotensin II at the AT? receptor, preventing vasoconstriction and aldosterone-mediated sodium retention ? reduces peripheral resistance and blood pressure.
- Amlodipine: Inhibits calcium ion influx through L-type channels in vascular smooth muscle ? vasodilation and reduced systemic vascular resistance.
- Chlorthalidone: Inhibits sodium and chloride reabsorption in the early distal tubules ? increases urinary excretion of sodium, chloride, and water ? reduces plasma volume and blood pressure.
Combined Effect: Triple antihypertensive action via RAAS blockade, vascular smooth muscle relaxation, and volume reduction ? synergistic and sustained BP lowering with improved 24-hour control.
Indications
- Essential hypertension not adequately controlled by dual combination therapy
- High cardiovascular risk patients needing aggressive BP control
Dosage Forms
- Telmisartan 40 mg + Amlodipine 5 mg + Chlorthalidone 12.5 mg
- Telmisartan 80 mg + Amlodipine 5 mg + Chlorthalidone 12.5 mg
Advantages of Triple Combination
- Complementary mechanisms ? enhanced BP reduction
- Better 24-hour BP control and reduced BP variability
- Lower dose-related adverse effects compared to high-dose monotherapy
- Chlorthalidone’s diuretic effect offsets amlodipine-induced pedal edema
- Improves patient compliance via single-pill regimen
Drug Interactions
- Potassium supplements / potassium-sparing diuretics ? hyperkalemia risk
- NSAIDs ? may reduce antihypertensive effect, risk of renal impairment
- Lithium ? increased lithium levels/toxicity
- CYP3A4 inhibitors/inducers ? may alter amlodipine metabolism
